[EN] PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1, 2 , 4]0XADIAZ0L-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS [FR] DERIVES DE PYRROLE UTILISES EN TANT QUE MODULATEURS ALLOSTERIQUES POSITIFS DES RECEPTEURS DE GLUTAMATE METABOTROPIQUE
Novel compounds and methods for preparing same, immunopotentiating compositions, and a method for potentiating the immune system of a host animal. The method comprises administering to the animal an effective amount of an immunopotentiating compound of Formula I or Formula II, or a physiologically acceptable salt.
[EN] ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] MODULATEURS ALLOSTERIQUES DE RECEPTEURS GLUTAMATE METABOTROPIQUES
申请人:ADDEX PHARMACEUTICALS SA
公开号:WO2005044797A1
公开(公告)日:2005-05-19
The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, Rl and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
Allosteric Modulators of Metabotropic Glutamate Receptors
申请人:Bessis Anne-Sophie
公开号:US20070219187A1
公开(公告)日:2007-09-20
The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R
1
and R
2
are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
Allosteric modulators of metabotropic glutamate receptors
申请人:Addex Pharma SA
公开号:US08163775B2
公开(公告)日:2012-04-24
The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
申请人:Bessis Anne-Sophie
公开号:US20110112143A1
公开(公告)日:2011-05-12
The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R
1
and R
2
are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.